{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","slug":"fondazione-irccs-istituto-nazionale-dei-tumori-milano","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"5-fluorouracil,leucovorin,panitumumab","genericName":"5-fluorouracil,leucovorin,panitumumab","slug":"5-fluorouracil-leucovorin-panitumumab","indication":"Metastatic colorectal cancer (Phase 2 investigation)","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Promensil","genericName":"Promensil","slug":"promensil","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"5-fluorouracil,leucovorin,panitumumab","genericName":"5-fluorouracil,leucovorin,panitumumab","slug":"5-fluorouracil-leucovorin-panitumumab","phase":"phase_2","mechanism":"This combination uses 5-fluorouracil and leucovorin as chemotherapy agents to inhibit thymidylate synthase and enhance fluorouracil cytotoxicity, while panitumumab blocks EGFR signaling to prevent tumor cell growth and survival.","indications":["Metastatic colorectal cancer (Phase 2 investigation)"],"catalyst":""},{"name":"Promensil","genericName":"Promensil","slug":"promensil","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1ZZHVpVl94VFJMQ0xpOUtYazd1SU00OUo3UWY3YmNZNG1MLUV5VEVrenlPeERvVHZLNlUtOTBCMDREUEtXQnVYOUp0T1hfeks5dXk5NUhlSk9DcE9qZzQ0?oc=5","date":"2024-03-08","type":"trial","source":"nature.com","summary":"Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study - nature.com","headline":"Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBueEQxYmZVdDZFQW51YzZudTAyY0tlLTl6NHJidWRDNy1GTmpWT083VVpxWndBWUtnLWNuODA3OGpOUnRlOGNpd2g4Y0g3ckZiRm1rR2s2V09xUW9kMXpR?oc=5","date":"2023-12-01","type":"pipeline","source":"nature.com","summary":"Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients - nature.com","headline":"Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5TdDBRMWVHNGMwXzlialhoVnVZVjVEdnd4RS1tU2RIcGhVczhDd3ktSDlZMVNOUW5CQ2pIUzQzQ3ItcV9yeDVNWkZpS1JnaHduTnpYdmYyd1FkZHZWVzY4?oc=5","date":"2023-01-18","type":"trial","source":"nature.com","summary":"Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study | Leukemia - nature.com","headline":"Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxPQkg5Z01hRzAxYkxRQ1dmeTdfUFp5ZVVURVNsdHJvSUgzOWY2TVJfLVA5UzhUZTdPcnd1YXU4SDJmaXM3b3lsd2o0SnQ1endQZmN0UTVSSnltNlpVX29BMHZVd01QWFV4TEdUd3VBdnlIMTNXY0MtRlBqOGZwT3pySWtFM2pnM1AwS3NXU1p4WlhqNUdjelUtQnFnVmpMcUh2ZjdaakhqZWVsM0FpZkVSR2FZWTlXOVF4SHNSeGtxTDlYenVzSk4yWnM4V2tFSm5kQmZKN1lPNXNxUUVSOEZpWGUxejExT2dFMW03STNWemFlMjhBUWJYLVh0RjlPdmpqSmFaU1pLZkxuMDRSYjZzYjJjVnRTbmdLMXJHRFlvQk1zUQ?oc=5","date":"2022-12-05","type":"pipeline","source":"European Medical Journal","summary":"Targeting Fibroblast Growth Factor Receptor Alterations in Cholangiocarcinoma and Other Solid Tumours: A New Frontier in Personalised Medicine - European Medical Journal","headline":"Targeting Fibroblast Growth Factor Receptor Alterations in Cholangiocarcinoma and Other Solid Tumours: A New Frontier in","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBxbW56NWlEOE9URGFHSEJqVy1TQ2RLb1ZCekpWQjZwc2lVbHlDR19zMUhaYzA1UzVjVHFnclNWRWVJZFV4QU85b1VuSDNGcUIyNWpidHBJeGY2Q0syQ1Vn?oc=5","date":"2019-10-03","type":"pipeline","source":"nature.com","summary":"Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients - nature.com","headline":"Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}